<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/39E6A660-94BC-427C-9ACD-28C18EDFA36E"><gtr:id>39E6A660-94BC-427C-9ACD-28C18EDFA36E</gtr:id><gtr:name>Proveca Limited</gtr:name><gtr:address><gtr:line1>DARESBURY INNOVATION CENTRE KECKWICK LANE , DARESBURY</gtr:line1><gtr:city>WARRINGTON</gtr:city><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39E6A660-94BC-427C-9ACD-28C18EDFA36E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>39E6A660-94BC-427C-9ACD-28C18EDFA36E</gtr:id><gtr:name>Proveca Limited</gtr:name><gtr:address><gtr:line1>DARESBURY INNOVATION CENTRE KECKWICK LANE , DARESBURY</gtr:line1><gtr:city>WARRINGTON</gtr:city><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24342.0</gtr:offerGrant><gtr:projectCost>40570.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700094"><gtr:id>A910ECD8-3B8E-4900-B501-7107CEBB736C</gtr:id><gtr:title>Novel glycopyrronium formulation for the treatment of severe chronic drooling in children</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700094</gtr:grantReference><gtr:abstractText>Sialorrhea or Chronic Drooling (CD) in children is a significant problem and can occur as the
manifestation of different neurological disorders such as cerebral palsy (CP) and amyotrophic
lateral sclerosis (ALS).
Proveca?s objective is to develop a novel oral formulation of glycopyrronium, an off-patent
drug for the treatment of sialorrhea or Chronic Drooling (CD) in children.
As Glycopyrronium is currently unlicensed in the UK and the rest of the EU for children,
Proveca has the opportunity to undertake the required clinical studies and apply for a
Paediatric Use Marketing Authorisation (PUMA) to target the children market in these
regions.
The world market for prescription paediatric drug was estimated to have reached $43 billion
in 2011 and to grow to $85 billion by 2017, this growth being mainly driven by new
regulations like PUMA recently introduced to incentivize the development and
commercialisation of paediatric drugs.
The innovation lies in developing a new licensed oral formulation of Glycopyrronium, which
unlike tablet formulation does not require compounding before administration. R&amp;amp;D activities
will involve conducting the required clinical trials to assess the drug efficacy.
The key objective of this Proof of Market project is to assess the commercial viability of
Proveca?s new
Glycopyrronium, to establish a full validation of the UK and EU market, gaining a thorough
understanding of the real needs and requirements of the patients, clinicians, GPs, pharma
companies and other stakeholders for the novel formulation. The early mapping of the market
opportunities will significantly accelerate the development and realisation of the project and
the European scope of the research will help Proveca to understand the wider market
requirements.</gtr:abstractText><gtr:fund><gtr:end>2012-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24342</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700094</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>